The MELAcare Study: A New Method for Surveillance of Melanoma Patients
ConditionCutaneous Melanoma
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorHerlev and Gentofte Hospital
About this trial
The aim of this study is to evaluate a new method of follow-up for patients with low and intermediate risk (stages IA-IIA) melanoma. The investigators will compare different tools for patient support and education combined with clinician supported skin self-examination (SSE) to the current standard-of-care. The hypothesis is that meta-cognitive strategies and clinician supported SSE can lower fear of cancer recurrence (FCR) and promote effective SSE on a regular basis without compromising the detection of new primary melanomas and/or metastases.
Eligibility criteria
Qualifiers
Ability to read and understand Danish language
Willing and able to give written informed consent
Surgical treatment of a clinical stage IA-IIA melanoma within 3 months of inclusion
Disqualifiers
Advanced melanoma, clinical stages IIB, IIC, III, or IV
Patients with high risk of a new primary melanoma (dysplastic nevus syndrome, or family history of melanoma)
History of melanoma skin cancer prior to the index diagnosis
Previous cancer, excluding non-melanoma skin cancer
Trial design
Treatments tested in this trial
- The MelaCare intervention
Treatment groups
378 Participants
are divided into 2 treatment groupsSponsors and collaborators
Herlev and Gentofte Hospital
Lead sponsor
Danish Cancer Society
Collaborator
Source ClinicalTrials.gov